Drugs / JS213
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07480733 | Apr 2026 → Nov 2027 expected | cancer | Shanghai Junshi Bioscience Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT07309276 | Jan 2026 → Nov 2027 expected | lung cancer | Shanghai Junshi Bioscience Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JS213 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07480733 ↗ |
| Route | Intravenous | “JS213 will be administered by intravenous infusion on Day 1 of each 21-day cycle.” NCT07309276 ↗ |